Gastroenterology › Crohn’s Disease

AI-Driven Benefit-Risk Analysis for Crohn’s Disease

Crohn’s disease BRA encompasses anti-TNF biologics, gut-selective integrin inhibitors, IL-12/23 and IL-23 pathway agents, and emerging small molecules. ArcaScience delivers mechanism-specific safety profiling across infliximab, adalimumab, vedolizumab, ustekinumab, and risankizumab with infection risk modeling and biologic sequencing analysis.

See Platform Request Demo

3,000,000+

Patients with IBD globally

1,800+

IBD clinical trials analyzed

$22B

Global IBD therapeutics market

15+

Approved IBD agents tracked

Disease Overview

Why Crohn’s Disease Demands Specialized BRA

Crohn’s disease requires lifelong immunosuppressive therapy with multiple biologic switching events over a patient’s treatment journey. The interplay of infection susceptibility, immunogenicity-driven loss of response, and cumulative immunosuppression demands sophisticated longitudinal benefit-risk frameworks that account for treatment sequencing and combination strategies.

Anti-TNF Infection & Lymphoma Risk

Infliximab, adalimumab, and certolizumab pegol carry well-established risks of serious infections including tuberculosis reactivation, invasive fungal infections, and hepatitis B reactivation. Long-term anti-TNF exposure is associated with increased lymphoma risk, particularly hepatosplenic T-cell lymphoma in young males on combination immunosuppression with thiopurines, requiring nuanced duration-dependent BRA modeling.

Biologic Switching & Immunogenicity

Patients with Crohn’s disease frequently cycle through multiple biologic classes due to primary non-response or secondary loss of response driven by anti-drug antibody formation. BRA must model cumulative safety across sequential anti-TNF, anti-integrin (vedolizumab), and IL-23 (risankizumab, guselkumab) exposures, including wash-out period infection vulnerability and the evolving safety profile with each biologic line.

PML & Hepatotoxicity Monitoring

While vedolizumab’s gut-selective mechanism offers a favorable systemic safety profile, the broader integrin inhibitor class carries residual PML concern from natalizumab precedent. Ustekinumab and risankizumab show reassuring hepatic safety, but combination with methotrexate or azathioprine introduces liver toxicity monitoring requirements that must be incorporated into comprehensive IBD BRA frameworks.

Platform Capabilities

How ArcaScience Addresses Crohn’s Disease BRA

Our platform is configured with IBD-specific data, infection risk prediction models, biologic immunogenicity analytics, and regulatory templates aligned with gastroenterology submission requirements across FDA, EMA, and PMDA.

Data Intelligence

IBD Data Coverage

1,800+ IBD clinical trials including SONIC, GEMINI, UNITI, U-EXCEL, U-EXCEED, ADVANCE, and MOTIVATE datasets. Adverse event data covering anti-TNF infection rates, vedolizumab nasopharyngitis and arthralgia, ustekinumab injection site reactions, and risankizumab hepatic enzyme elevations across luminal, fistulizing, and perianal disease phenotypes.

Explore Data Engine →

Decision Intelligence

Biologic Sequencing AI Models

AI models for infection risk stratification across biologic classes, anti-drug antibody prediction and immunogenicity-adjusted BRA, comparative safety profiling between anti-TNF, anti-integrin, and IL-23 mechanisms, and TB reactivation risk scoring. BRAT framework application with IBD-specific regulatory precedent from FDA and EMA gastroenterology divisions.

Explore AI Models →

Automated Outputs

IBD Regulatory Outputs

PSURs with infection safety deep-dives for anti-TNF and biologic agents, RMPs with TB screening protocols and progressive multifocal leukoencephalopathy monitoring, CTD 2.5 with CDAI, SES-CD, and PRO endpoint summaries, and HEOR reports supporting payer submissions for biologic and biosimilar agents.

Explore Outputs →

Crohn’s Disease Intelligence

Platform Performance in Crohn’s Disease

8,500,000,000+

IBD adverse event data points

55%

Faster infection signal detection

Biologic classes modeled for sequencing

IBD regulatory submissions supported

Case Evidence — Crohn’s Disease

Biologic Switching Safety Across Anti-TNF, IL-23, and Integrin Classes

Challenge

A mid-size biotech developing a novel IL-23 inhibitor for Crohn’s disease needed to demonstrate a favorable benefit-risk profile in biologic-experienced patients who had failed one or more anti-TNF agents. Regulatory agencies required comprehensive safety comparisons across biologic classes and analysis of cumulative immunosuppression risk in heavily pretreated populations.

Result

ArcaScience deployed biologic sequencing models that analyzed infection rates, immunogenicity patterns, and efficacy-safety tradeoffs across treatment lines. The platform identified that IL-23 inhibitors maintained consistent safety profiles regardless of prior anti-TNF exposure, with 40% lower serious infection rates compared to continued anti-TNF therapy in treatment-refractory patients. This analysis directly supported a successful regulatory filing.

40%

Lower infection rate vs continued anti-TNF

2.8x

Faster safety signal characterization

View All Case Studies →

ArcaScience’s ability to model safety across biologic sequences was critical for our regulatory strategy. The platform demonstrated that our IL-23 inhibitor maintained its safety advantage even in anti-TNF-experienced patients, which was the key differentiator in our submission narrative.

VP, Gastroenterology Clinical Development

Mid-Size Biotech Company

Frequently Asked Questions

Crohn’s Disease Benefit-Risk Analysis

Our platform models benefit-risk separately for luminal, stricturing, and fistulizing Crohn’s disease phenotypes, recognizing that treatment goals and acceptable risk thresholds differ significantly. For fistulizing disease, where infliximab remains a cornerstone, the BRA framework accounts for higher acceptable infection risk given the severity of disease burden. For luminal disease with multiple therapeutic options, comparative safety across biologic classes drives the benefit-risk assessment, including quality-of-life endpoints like fatigue, abdominal pain, and bowel frequency alongside traditional safety metrics.

Yes. ArcaScience models cumulative safety across sequential biologic exposures, including anti-TNF to anti-TNF switching (e.g., infliximab to adalimumab), anti-TNF to vedolizumab, anti-TNF to ustekinumab, and emerging IL-23 class agents like risankizumab and guselkumab. The platform tracks immunogenicity-driven loss of response events, wash-out period infection vulnerability, and the evolving baseline risk as patients accumulate prior biologic exposures. This enables regulatory-grade safety assessments for agents positioning as second- or third-line biologic options.

With multiple infliximab and adalimumab biosimilars now approved, our platform provides comprehensive switching safety analysis incorporating data from NOR-SWITCH and other interchangeability studies. We model anti-drug antibody dynamics during originator-to-biosimilar transitions, track potential immunogenicity amplification with multiple switches, and provide pharmacovigilance-grade analysis for payer and regulatory submissions supporting biosimilar adoption. The platform also covers the emerging landscape of adalimumab high-concentration biosimilars and their injection site reaction profiles.

Pediatric Crohn’s disease presents unique BRA challenges including growth delay impact assessment, vaccination considerations during immunosuppression, hepatosplenic T-cell lymphoma risk in adolescent males on anti-TNF plus thiopurine combinations, and the decades-long treatment horizon requiring cumulative safety modeling. Our platform incorporates pediatric-specific dosing pharmacokinetics, weight-based exposure models, and developmental milestone tracking alongside traditional safety endpoints. We also model the benefit-risk of top-down versus step-up treatment strategies in newly diagnosed pediatric patients.

Our platform integrates data from major IBD registries including TREAT, PYRAMID, and PSOLAR alongside claims databases, electronic health records, and post-marketing surveillance reports. This real-world evidence captures long-term safety signals that clinical trials cannot adequately power for, such as rare lymphoma events, opportunistic infection patterns in elderly IBD patients, and safety outcomes in patients with comorbidities typically excluded from registration trials. The platform reconciles trial-based and real-world safety data using Bayesian meta-analytic frameworks calibrated for IBD-specific confounders.

See ArcaScience Applied to Crohn’s Disease

Request a demonstration of ArcaScience’s platform configured for Crohn’s disease benefit-risk analysis. Our gastroenterology scientists will walk through biologic sequencing models, infection risk prediction, and regulatory output examples tailored to IBD submissions.

Request Crohn’s Disease Briefing Explore the Platform →